109 related articles for article (PubMed ID: 23734840)
1. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study.
Watanabe M; Nishino H; Sameshima Y; Ota A; Nakamura S; Hibi T
Aliment Pharmacol Ther; 2013 Aug; 38(3):264-73. PubMed ID: 23734840
[TBL] [Abstract][Full Text] [Related]
2. Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials.
Dignass A; Stremmel W; Horyński M; Poyda O; Armerding P; Fellermann K; Langhorst J; Kuehbacher T; Uebel P; Stein J; Novacek G; Avalueva E; Oliinyk O; Hasselblatt P; Dorofeyev A; Heinemann H; Mueller R; Greinwald R; Reinisch W;
Clin Gastroenterol Hepatol; 2024 Apr; 22(4):810-820.e7. PubMed ID: 37806372
[TBL] [Abstract][Full Text] [Related]
3. Mesalazine dose modification based on faecal calprotectin levels in patients with ulcerative colitis in clinical remission.
Piñero G; Mañosa M; Calafat M; Vayreda E; Cañete F; Puig M; Domènech E
Gastroenterol Hepatol; 2024; 47(6):612-619. PubMed ID: 37806344
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine.
Prenzler A; Yen L; Mittendorf T; von der Schulenburg JM
BMC Health Serv Res; 2011 Jul; 11():157. PubMed ID: 21729262
[TBL] [Abstract][Full Text] [Related]
5. Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine.
Russo L; Schneider G; Gardiner MH; Lanes S; Streck P; Rosen S
Eur J Clin Pharmacol; 2014 Jun; 70(6):709-17. PubMed ID: 24609467
[TBL] [Abstract][Full Text] [Related]
6. Qingchang suppositry induced remission in patients with mild-to-moderate ulcerative proctitis: a multicenter, prospective, randomized, parallel-controlled clinical trial.
Xiaoling D; Anming Z; Hui L; Bei S; Yi R; Hongzhu W; Xiaoyan F; Jiang L
J Tradit Chin Med; 2024 Feb; 44(1):156-162. PubMed ID: 38213250
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of traditional Chinese medicine on mild active ulcerative colitis: A multi-center, randomized, double-blind, controlled trial.
Kou FS; Shi L; Li JX; Wang ZB; Shi R; Mao TY; Ke X; Zhang BP; Yang XJ; Wen XL; Zheng WY; Han X; Ding PH; Dong J
Medicine (Baltimore); 2020 Aug; 99(35):e21903. PubMed ID: 32871923
[TBL] [Abstract][Full Text] [Related]
8. Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.
Saini SD; Waljee AK; Higgins PD
Clin Gastroenterol Hepatol; 2012 Oct; 10(10):1143-51. PubMed ID: 22610010
[TBL] [Abstract][Full Text] [Related]
9. Distinct kinetics in the frequency of peripheral CD4+ T cells in patients with ulcerative colitis experiencing a flare during treatment with mesalazine or with a herbal preparation of myrrh, chamomile, and coffee charcoal.
Langhorst J; Frede A; Knott M; Pastille E; Buer J; Dobos GJ; Westendorf AM
PLoS One; 2014; 9(8):e104257. PubMed ID: 25144293
[TBL] [Abstract][Full Text] [Related]
10. The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine.
Yarlas A; Willian MK; Nag A
Qual Life Res; 2021 Jul; 30(7):1925-1938. PubMed ID: 33651279
[TBL] [Abstract][Full Text] [Related]
11. Mesalazine-induced esophageal ulcers. A rare adverse effect.
Díaz Molina RJ; Comesaña Castellar C; García Hernández M; Garrido Durán C; Martínez Ortega MA; Ginard Vicens D
Rev Esp Enferm Dig; 2024 May; 116(5):294-295. PubMed ID: 37350665
[TBL] [Abstract][Full Text] [Related]
12. Similar Efficacy of Mesalazine in Adult and Older Adult Ulcerative Colitis Patients: Post Hoc Analysis of a Randomized Noninferiority Trial of 1600 mg vs 400 mg Tablets.
Safroneeva E; Thorne H; Gerstner O; Laoun R
Inflamm Bowel Dis; 2024 Jun; ():. PubMed ID: 38902993
[TBL] [Abstract][Full Text] [Related]
13. The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study.
Verstockt B; Vermeire S; Peyrin-Biroulet L; Mosig R; Feagan BG; Colombel JF; Siegmund B; Rieder F; Schreiber S; Yarur A; Panaccione R; Dubinsky M; Lichtiger S; Cataldi F; Danese S
J Crohns Colitis; 2024 May; 18(5):762-772. PubMed ID: 37952114
[TBL] [Abstract][Full Text] [Related]
14. Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.
Hussain FN; Ajjan RA; Riley SA
Br J Clin Pharmacol; 2000 Apr; 49(4):323-30. PubMed ID: 10759687
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
Peyrin-Biroulet L; Dubinsky MC; Sands BE; Panés J; Schreiber S; Reinisch W; Feagan BG; Danese S; Yarur AJ; D'Haens GR; Goetsch M; Wosik K; Keating M; Lazin K; Wu J; Modesto I; McDonnell A; Bartolome L; Vermeire S
J Crohns Colitis; 2024 Apr; ():. PubMed ID: 38613425
[TBL] [Abstract][Full Text] [Related]
16. A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis.
D'Haens G; Peyrin-Biroulet L; Marks DJB; Lisi E; Liefaard L; Beaton A; Srinivasan N; Bouma G; Prasad N; Cameron R; Kayali Z; Tarzi R; Hanauer S; Sandborn WJ
Aliment Pharmacol Ther; 2023 Aug; 58(3):283-296. PubMed ID: 37323059
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and tolerability of rectal ointment and suppositories containing sucralfate for hemorrhoidal symptoms: a prospective, observational study.
Marik AR; Miklós I; Csukly G; Hársfalvi P; Novák A
Int J Colorectal Dis; 2024 May; 39(1):72. PubMed ID: 38750150
[TBL] [Abstract][Full Text] [Related]
18. Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents.
Yasutomi E; Hiraoka S; Yamamoto S; Oka S; Hirai M; Yamasaki Y; Inokuchi T; Kinugasa H; Takahara M; Harada K; Kato J; Okada H
J Clin Med; 2019 Dec; 8(12):. PubMed ID: 31810227
[TBL] [Abstract][Full Text] [Related]
19. Environmental enteropathy and malnutrition: do we know enough to intervene?
Petri WA; Naylor C; Haque R
BMC Med; 2014 Oct; 12():187. PubMed ID: 25604120
[TBL] [Abstract][Full Text] [Related]
20. Aligning oral mesalazine treatment to health service priorities: guidance for nurses.
Kemp K; Sephton M
Frontline Gastroenterol; 2014 Apr; 5(2):135-142. PubMed ID: 24683448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
